Grm2 — Glutamate Metabotropic Receptor 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GRM2 (Glutamate Metabotropic Receptor 2) encodes the metabotropic glutamate receptor 2 (mGluR2), a Group I metabotropic glutamate receptor that modulates glutamatergic neurotransmission in the central nervous system.
| Attribute |
Value |
| Gene Symbol |
GRM2 |
| Full Name |
Glutamate Metabotropic Receptor 2 |
| Chromosomal Location |
3p21.31 |
| NCBI Gene ID |
2913 |
| OMIM |
604099 |
| Ensembl ID |
ENSG00000164038 |
| UniProt |
Q14416 |
The GRM2 gene encodes mGluR2, a 872 amino acid G protein-coupled receptor.
- UniProt ID: Q14416
- Molecular Weight: ~95 kDa
- Subcellular Localization: Postsynaptic membrane, presynaptic terminals
- Protein Family: Class C GPCR, mGluR family
mGluR2 is a presynaptic autoreceptor that negatively regulates glutamate release. It plays a critical role in:
- Synaptic Transmission: Modulates excitatory neurotransmission by inhibiting voltage-gated calcium channels
- Neuroprotection: Activation reduces excitotoxicity by decreasing glutamate release
- Learning and Memory: Involved in synaptic plasticity mechanisms
- Gene Expression: Activates downstream signaling cascades including MAPK/ERK and PI3K pathways
- mGluR2 signaling is dysregulated in AD brains
- Amyloid-beta affects mGluR2 function and trafficking
- mGluR2 modulators may have therapeutic potential
- Altered mGluR2 signaling in the striatum
- Potential target for motor dysfunction
- Genetic associations with schizophrenia risk
- mGluR2/3 agonists being investigated
- mGluR2 dysfunction linked to seizure susceptibility
High expression in:
- Cerebral cortex (layers II-III)
- Hippocampus (CA1-CA3)
- Basal ganglia (striatum)
- Cerebellum (granule cell layer)
- Olfactory bulb
| Agent |
Mechanism |
Status |
Indication |
| LY341495 |
mGluR2/3 antagonist |
Research |
- |
| DCG-IV |
mGluR2 agonist |
Research |
Neuroprotection |
- Conn PJ, et al. (2009). Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. PMID:18928405
- Nicoletti F, et al. (2011). Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology. PMID:20950656
- Wang H, et al. (2017). mGluR2 as a therapeutic target in neurodegenerative diseases. Front Pharmacol. PMID:29213235
mGluR2 is a promising drug target for several neurological conditions:
| Drug/Compound |
Mechanism |
Status |
Indication |
| LY379268 |
mGluR2/3 agonist |
Research |
Schizophrenia, depression |
| MGS0039 |
mGluR2/3 antagonist |
Research |
Depression, anxiety |
| Pomaglumetad methionil |
mGluR2/3 agonist |
Phase II |
Schizophrenia |
| ADX71149 |
mGluR2 positive allosteric modulator |
Research |
Anxiety, schizophrenia |
| JNJ-46281222 |
mGluR2 negative allosteric modulator |
Research |
Depression |
- mGluR2 modulation affects amyloid processing
- mGluR2 activation reduces Aβ-induced toxicity
- Group II mGluRs are neuroprotective
- Synaptic plasticity modulation is therapeutic target
- mGluR2/3 agonists reduce motor symptoms
- Dysregulation of glutamatergic signaling in PD
- mGluR2 as target for levodopa-induced dyskinesias
- Excitotoxicity involves mGluR2/3 signaling
- mGluR4 is more prominently studied in ALS
- Modulation affects motor neuron survival
mGluR2 couples to Gi/o proteins, leading to:
- Adenylyl cyclase inhibition: Reduces cAMP production
- MAPK/ERK pathway modulation: Affects gene transcription
- PI3K/Akt signaling: Promotes neuronal survival
- Ion channel modulation: K+ channel activation
- NF-κB pathway: Affects inflammatory responses
- Grn2-/- mice: Knockout mice show hyperactivity and enhanced learning
- mGluR2 transgenic models: Overexpression studies
- AAV-mediated expression: Viral vector approaches
- Conditional knockout: Region-specific deletion studies
- Development of brain-penetrant mGluR2 modulators
- Understanding mGluR2/3 receptor subtype selectivity
- Clinical trials for psychiatric indications
- Biomarker development for patient selection
The study of Grm2 — Glutamate Metabotropic Receptor 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Conn PJ, et al. Metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 2000.
[2] Nicoletti F, et al. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology. 2011.
[3] Cleva RM, et al. mGluR2/3 and mGluR5 in Parkinson's disease. Neuropharmacology. 2011.
[4] Austin PJ, et al. mGlu2 receptors in neurodegenerative disease. J Neurochem. 2014.
[5] Liu J, et al. mGluR2 in Alzheimer's disease. Front Cell Neurosci. 2016.